261 related articles for article (PubMed ID: 10948855)
1. Trends of AIDS in Guadeloupe (French West Indies) a longitudinal survey from 1988 to 1997.
Deloumeaux J; Foucan L; Sow-Goerger MT; Contamin B; Strobel M
West Indian Med J; 2000 Jun; 49(2):148-53. PubMed ID: 10948855
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
[TBL] [Abstract][Full Text] [Related]
3. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
Nightingale SD; Jockusch JD; Haslund I; Cal SX; Peterson DM; Loss SD
Arch Intern Med; 1993 Jun; 153(11):1313-8. PubMed ID: 8099477
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
5. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
6. [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].
Mary-Krause M; Rabaud C; Jouan M; Obadia M; de la Blanchardière A; Raffi F; May T
Pathol Biol (Paris); 2000 Jun; 48(5):495-504. PubMed ID: 10949848
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count.
Rockstroh JK; Woitas RP; Brackmann HH; Kupfer B; Kaiser R; Schneweis KE; Sudhop T; Spengler U
Eur J Med Res; 1998 May; 3(5):223-30. PubMed ID: 9580568
[TBL] [Abstract][Full Text] [Related]
8. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with blood-borne AIDS in Italy.
Bellocco R; Xu J; Schinaia N; Arcieri R; Pagano M
J Epidemiol Biostat; 2000; 5(2):79-87. PubMed ID: 10890279
[TBL] [Abstract][Full Text] [Related]
10. [Survival of patients with AIDS treated with protease inhibitors].
Martínez Avilés P; Berbegal Serra J; López Benito I
An Med Interna; 1999 May; 16(5):225-8. PubMed ID: 10389306
[TBL] [Abstract][Full Text] [Related]
11. Transfusion associated AIDS in Mexico. Clinical spectrum, conditional latency distribution, and survival.
Volkow P; Ponce de León S; Calva J; Ruiz-Palacios G; Mohar A
Rev Invest Clin; 1993; 45(2):133-8. PubMed ID: 8337540
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.
Sungkanuparph S; Chakriyanuyok T; Butthum B
J Infect; 2008 Jan; 56(1):40-3. PubMed ID: 18037166
[TBL] [Abstract][Full Text] [Related]
13. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
14. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
[TBL] [Abstract][Full Text] [Related]
15. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
Mocroft A; Phillips AN; Friis-Møller N; Colebunders R; Johnson AM; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren JD;
Antivir Ther; 2002 Mar; 7(1):21-30. PubMed ID: 12008784
[TBL] [Abstract][Full Text] [Related]
16. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
17. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for the survival of patients with AIDS cholangiopathy.
Ko WF; Cello JP; Rogers SJ; Lecours A
Am J Gastroenterol; 2003 Oct; 98(10):2176-81. PubMed ID: 14572564
[TBL] [Abstract][Full Text] [Related]
19. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
20. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.
García de Olalla P; Martínez-González MA; Caylà JA; Jansà JM; Iglesias B; Guerrero R; Marco A; Gatell JM; Ocaña I;
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1051-7. PubMed ID: 12546112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
